Table 2.
The Characteristics of the Included Studies
| Characteristic | Number* | Percentage (%) |
|---|---|---|
| Publication year | ||
| 2022 | 2 | 25 |
| 2021 | 2 | 25 |
| 2020 | 3 | 37.5 |
| 2019 | 1 | 12.5 |
| Country | ||
| India | 2 | 25 |
| China | 1 | 12.5 |
| French | 1 | 12.5 |
| Lebanon | 1 | 12.5 |
| Singapore | 1 | 12.5 |
| Republic of Korea | 1 | 12.5 |
| Greece | 1 | 12.5 |
| Study design | ||
| Cross-sectional study | 7 | 87.5 |
| Qualitative study | 1 | 12.5 |
| Target population | ||
| Ischemic stroke | 7 | 58.33 |
| Transient ischemic attack | 3 | 25 |
| Acute ischemic stroke | 1 | 8.33 |
| Hemorrhagic stroke | 1 | 8.33 |
| Sample size (n) | ||
| 1–50 | 1 | 12.5 |
| > 50–100 | 1 | 12.5 |
| > 100–200 | 3 | 37.5 |
| > 200–300 | 2 | 25 |
| > 300 | 1 | 12.5 |
| Medication adherence measurement | ||
| The shortened Medication Adherence Report Scale (MARS-5) | 3 | 37.5 |
| The 8-item Morisky Medication Adherence Scale (MMAS) | 1 | 12.5 |
| The Lebanese Medication Adherence Scale (LMAS-14) | 1 | 12.5 |
| Semi-structured interview | 1 | 12.5 |
| Self-report** | 1 | 12.5 |
| A medication adherence assessment questionnaire was developed based on the patients’ common problems | 1 | 12.5 |
Notes: *The number of included studies in which one study may contribute to > 1 characteristic. **Self-reported medication adherence was defined as the consumption of at least > 80% of their medications for the last two weeks, based on the patient’s last prescription.